PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Shanghai Hengrui Medicine Co. Ltd.	07/08/2010

RECEIVING PARTY DATA

Name:	Jiangsu Hengrui Medicine Co. Ltd.
Street Address:	No. 145, East Renmin Road
Internal Address:	Xinpu
City: Lianyungang, Jiangsu State/Country: CHINA	

Name:	Shanghai Hengrui Pharmaceutical Co. Ltd.
Street Address:	279 Wenjing Road
Internal Address: Minhang	
City:	Shanghai
State/Country:	CHINA
Postal Code:	200245

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	12743795

CORRESPONDENCE DATA

Fax Number: (312)321-4299

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 3123214200

Email: sriley@usebrinks.com

Correspondent Name: Yuezhong Feng

Address Line 1: Brinks Hofer Gilson & Lione

Address Line 2: P.O. Box 10395

PATENT

REEL: 024732 FRAME: 0580

CH \$40.00 12/43/9

501241955

Address Line 4: Chicago, ILLINOIS 60610		
ATTORNEY DOCKET NUMBER:	14271/3	
NAME OF SUBMITTER:	Yuezhong Feng, Ph.D.	
Total Attachments: 2 source=14271_3_assignment#page1.tif source=14271_3_assignment#page2.tif		

PATENT REEL: 024732 FRAME: 0581

ASSIGNMENT

WHEREAS, <u>Shanghai Hengrui Medicine Co. Ltd.</u>, hereinafter called the "Assignor", has acquired the entire right, title and interest in and to the invention described in the United States patent application entitled <u>TETRAHYDRO-IMIDAZO[1,5-\alpha]PYRAZINE DERIVATIVES</u>, <u>PREPARATION PROCESS AND MEDICINAL USE THEREOF</u>, for a full description of which reference is here made to an application for Letters Patent of the United States filed on <u>May 19, 2010</u> and assigned Application Serial No. <u>12/743,795</u>, and all patents which may be obtained for said invention;

WHEREAS, <u>Jiangsu Hengrui Medicine Co. Ltd.</u>, a corporation organized and existing under the laws of <u>China</u>, having a place of business at <u>No. 145</u>, <u>East Renmin Road</u>, <u>Xinpu</u>, <u>Lianyungang</u>, <u>Jiangsu 222002</u>, <u>China</u>, and <u>Shanghai Hengrui Pharmaceutical Co. Ltd.</u>, a corporation organized and existing under the laws of <u>China</u>, having a place of business at <u>279 Wenjing Road</u>, <u>Minhang</u>, <u>Shanghai 200245</u>, <u>China</u>, hereinafter collectively called the "Assignee", desires to acquire the entire right, title and interest in and to the invention and the patent application identified above, and all patents which may be obtained for said invention, as set forth below;

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00), and other valuable and legally sufficient consideration, the receipt of which by the Assignor from the Assignee is hereby acknowledged, the Assignor has sold, assigned and transferred, and by these presents does sell, assign and transfer to the Assignee, the entire right, title and interest for the United States in and to the invention and the patent application identified above, and any patents that may issue for said invention in the United States; together with the entire right, title and interest in and to said invention and all patent applications and patents issuing therefrom in all countries foreign to the United States, including the full right to claim for any such application all benefits and priority rights under any applicable convention; together with the entire right, title and interest in and to all continuations, divisions, renewals and extensions of any of the patent applications and patents defined above; together with the right to recover all damages, including, but not limited to, a reasonable royalty, by reason of past, present,

PATENT REEL: 024732 FRAME: 0582 or future infringement or any other violation of patent or patent application rights; to have and to hold for the sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents. The Assignor hereby sells, assigns, and transfers the entire right, title and interest to the Assignee as of the day of filing the application identified above.

The Assignor hereby covenants and agrees, for both the Assignor and the Assignor's legal representatives, that the Assignor will assist the Assignee in the prosecution of the patent application identified above; in the making and prosecution of any other patent applications that the Assignee may elect to make covering the invention identified above; in vesting in the Assignee like exclusive title in and to all such other patent applications and patents; and in the prosecution of any interference which may arise involving said invention, or any such patent application or patent; and that the Assignor will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignee to carry out the terms of this Assignment.

The Commissioner of Patents and Trademarks is hereby authorized and requested to issue patents to the Assignee in accordance with the terms of this Assignment.

IN TESTIMONY WHEREOF, the Assignor has executed this agreement.

DATED:	2010-7-8	Shanghai Hengrui Medicine Co. Ltd.
		Shanghai Hengrui Medićine Co. Ltd.
WITNESSED:		
DATE:	20/0-7-8	Wang, Qian
DATE:	>010-7-8	TANG, xiaowei

RECORDED: 07/23/2010